Standout Papers

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: ... 2021 2026 2022 2024203
  1. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study (2021)
    Martin Hutchings, Rogier Mous et al. The Lancet

Immediate Impact

53 standout
Sub-graph 1 of 22

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
8 intermediate papers

Works of Brian Elliott being referenced

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
2021 Standout
Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data
2020
and 2 more

Author Peers

Author Last Decade Papers Cites
Brian Elliott 339 248 112 31 456
M. Dorreen 150 177 49 23 388
Ivo Radman 140 151 54 42 407
Ryan Jacobs 164 179 117 56 473
A E Dewar 108 183 87 33 479
Letizia Gandolfi 196 404 83 28 491
László Váróczy 83 219 48 44 411
Barbara Jezeršek Novaković 160 178 59 41 387
Leanne Berkahn 147 247 44 35 458
Francesco Grimaldi 120 110 45 29 449
Annunziata Manna 173 224 25 29 475

All Works

Loading papers...

Rankless by CCL
2026